Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters

eLife

Volumn 3, Issue July2014, 2014, Pages 1-19

  Johnson, Zachary Lee ^a   Lee, Jun Ho ^a   Lee, Kiyoun ^b   Lee, Minhee ^b   Kwon, Do Yeon ^b   Hong, Jiyong ^a,b   Lee, Seok Yong ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CARRIER PROTEIN; CIF NUCLEOSIDE TRANSPORTER; DEOXYCYTIDINE; GEMCITABINE; NUCLEOSIDE TRANSPORTER; PROTEIN BINDING; RECOMBINANT PROTEIN; RIBAVIRIN; URIDINE;

ANALOGS AND DERIVATIVES; ANIMAL; BINDING SITE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENZYME SPECIFICITY; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; KINETICS; METABOLISM; MOLECULAR DOCKING; OOCYTE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; TRANSPORT AT THE CELLULAR LEVEL; VIBRIO CHOLERAE; X RAY CRYSTALLOGRAPHY; XENOPUS LAEVIS;

ANIMALS; BACTERIAL PROTEINS; BINDING SITES; BIOLOGICAL TRANSPORT; CRYSTALLOGRAPHY, X-RAY; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION; HUMANS; KINETICS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR DOCKING SIMULATION; NUCLEOSIDE TRANSPORT PROTEINS; OOCYTES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECOMBINANT PROTEINS; RIBAVIRIN; SUBSTRATE SPECIFICITY; THERMODYNAMICS; URIDINE; VIBRIO CHOLERAE; XENOPUS LAEVIS;

EID: 84934272844     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.03604     Document Type: Article

References (60)

1. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. 2004. The equilibrative nucleoside transporter family, SLC29. Pflugers Archiv 447:735-743. doi: 10.1007/s00424-003-1103-2.
2. Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R. 2011. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Research 71:1825-1835. doi: 10.1158/0008-5472.CAN-10-2736.
3. Cano-Soldado P, Gorraitz E, Errasti-Murugarren E, Casado FJ, Lostao MP, Pastor-Anglada M. 2012. Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket. American Journal of Physiology Cell Physiology 302:C257-C266. doi: 10.1152/ajpcell.00198.2011.
4. Choi MK. 2012. Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells. Archives of Pharmacal Research 35:921-927. doi: 10.1007/s12272-012-0518-8.
5. Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE. 2006. The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine. Molecular Pharmacology 70:303-310. doi: 10.1124/mol.105.021543.
6. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE. 2003. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536. doi: 10.1038/sj.onc.1206952.
7. Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, Tong Z. 2012. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides, Nucleotides & Nucleic Acids 31:236-255. doi: 10.1080/15257770.2011.652330.
8. Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE. 2009. Human nucleoside transporters: biomarkers for response to nucleoside drugs. Nucleosides, Nucleotides & Nucleic Acids 28:450-463. doi: 10.1080/15257770903044499.
9. Damaraju VL, Smith KM, Mowles D, Nowak I, Karpinski E, Young JD, Robins MJ, Cass CE. 2011. Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: high-affinity inhibitors of human concentrative nucleoside transporter 1. Biochemical Pharmacology 81:82-90. doi: 10.1016/j.bcp.2010.09.009.
10. Doehring A, Hofmann WP, Schlecker C, Zeuzem S, Sarrazin C, Berg T, Muller T, Herrmann E, Geisslinger G, Lotsch J. 2011. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenetics and Genomics 21:289-296. doi: 10.1097/FPC.0b013e32834412e7.
11. Dunitz JD, Taylor R. 1997. Organic fluorine hardly ever accepts hydrogen bonds. Chemistry-A European Journal 3:89-98. doi: 10.1002/chem.19970030115.
12. Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, Pastor-Anglada M. 2004. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. International Journal of Cancer 112:959-966. doi: 10.1002/ijc.20524.
13. Fukao M, Ishida K, Sakamoto T, Taguchi M, Matsukura H, Miyawaki T, Hashimoto Y. 2011. Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug Metabolism and Pharmacokinetics 26:538-543. doi: 10.2133/dmpk.DMPK-11-NT-040.
14. Gao X, Lu F, Zhou L, Dang S, Sun L, Li X, Wang J, Shi Y. 2009. Structure and mechanism of an amino acid antiporter. Science 324:1565-1568. doi: 10.1126/science.1173654.
15. Graham KA, Leithoff J, Coe IR, Mowles D, Mackey JR, Young JD, Cass CE. 2000. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. Nucleosides, Nucleotides & Nucleic Acids 19:415-434. doi: 10.1080/15257770008033018.
16. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM. 2004a. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Molecular Pharmacology 65:512-519. doi: 10.1124/mol.65.3.512.
17. Gray JH, Owen RP, Giacomini KM. 2004b. The concentrative nucleoside transporter family, SLC28. Pflugers Archiv 447:728-734. doi: 10.1007/s00424-003-1107-y.
18. Hagenbuch B, Stieger B. 2013. The SLCO (former SLC21) superfamily of transporters. Molecular Aspects of Medicine 34:396-412. doi: 10.1016/j.mam.2012.10.009.
19. Han HK, Amidon GL. 2000. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2:E6.
20. He X, Szewczyk P, Karyakin A, Evin M, Hong WX, Zhang Q, Chang G. 2010. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 467:991-994. doi: 10.1038/nature09408.
21. Howard JAK, Hoy VJ, Ohagan D, Smith GT. 1996. How good is fluorine as a hydrogen bond acceptor? Tetrahedron 52:12613-12622. doi: 10.1016/0040-4020(96)00749-1.
22. Hu NJ, Iwata S, Cameron AD, Drew D. 2011. Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT. Nature 478:408-411. doi: 10.1038/nature10450.
23. Hunter CA, Sanders JKM. 1990. The Nature of pi-pi interactions. Journal of the American Chemical Society 112:5525-5534. doi: 10.1021/ja00170a016.
24. Johnson ZL, Cheong CG, Lee SY. 2012. Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å. Nature 483:489-493. doi: 10.1038/nature10882.
25. Jordheim LP, Dumontet C. 2007. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochimica et Biophysica Acta 1776:138-159. doi: 10.1016/j.bbcan.2007.07.004.
26. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. 2006. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends in Pharmacological Sciences 27:416-425. doi: 10.1016/j.tips.2006.06.004.
27. Koepsell H, Endou H. 2004. The SLC22 drug transporter family. Pflugers Archiv 447:666-676. doi: 10.1007/s00424-003-1089-9.
28. Krishnamurthy H, Piscitelli CL, Gouaux E. 2009. Unlocking the molecular secrets of sodium-coupled transporters. Nature 459:347-355. doi: 10.1038/nature08143.
29. Lane J, Martin TA, Mcguigan C, Mason MD, Jiang WG. 2010. The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. Journal of Experimental Therapeutics & Oncology 8:203-210.
30. Loewen SK, Ng AM, Yao SY, Cass CE, Baldwin SA, Young JD. 1999. Identification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na(+) nucleoside cotransporters hCNT1 and hCNT2. The Journal of Biological Chemistry 274:24475-24484. doi: 10.1074/jbc.274.35.24475.
31. Mackey JR, Baldwin SA, Young JD, Cass CE. 1998. Nucleoside transport and its significance for anticancer drug resistance. Drug Resistance Updates 1:310-324. doi: 10.1016/S1368-7646(98)80047-2.
32. Majumdar S, Duvvuri S, Mitra AK. 2004. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Advanced Drug Delivery Reviews 56:1437-1452. doi: 10.1016/j.addr.2004.02.006.
33. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Deviere J, Van Laethem JL. 2009. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clinical Cancer Research 15:2913-2919. doi: 10.1158/1078-0432.CCR-08-2080.
34. Molina-Arcas M, Casado FJ, Pastor-Anglada M. 2009. Nucleoside transporter proteins. Current Vascular Pharmacology 7:426-434. doi: 10.2174/157016109789043892.
35. Monecke T, Buschmann J, Neumann P, Wahle E, Ficner R. 2014. Crystal structures of the novel cytosolic 5'-nucleotidase IIIB explain its preference for m7GMP. PLOS ONE 9:e90915. doi: 10.1371/journal.pone.0090915.
36. Naito T, Tokashiki S, Mino Y, Otsuka A, Ozono S, Kagawa Y, Kawakami J. 2010. Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic & Clinical Pharmacology & Toxicology 106:310-316. doi: 10.1111/j.1742-7843.2009.00489.x.
37. Newstead S, Drew D, Cameron AD, Postis VL, Xia X, Fowler PW, Ingram JC, Carpenter EP, Sansom MS, Mcpherson MJ, Baldwin SA, Iwata S. 2011. Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2. The EMBO Journal 30:417-426. doi: 10.1038/emboj.2010.309.
38. Nishio M. 2011. The CH/pi hydrogen bond in chemistry. Conformation, supramolecules, optical resolution and interactions involving carbohydrates. Physical Chemistry Chemical Physics 13:13873-13900. doi: 10.1039/c1cp20404a.
39. Paproski RJ, Yao SY, Favis N, Evans D, Young JD, Cass CE, Zemp RJ. 2013. Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake. PLOS ONE 8:e56423. doi: 10.1371/journal.pone.0056423.
40. Pedersen BP, Kumar H, Waight AB, Risenmay AJ, Roe-Zurz Z, Chau BH, Schlessinger A, Bonomi M, Harries W, Sali A, Johri AK, Stroud RM. 2013. Crystal structure of a eukaryotic phosphate transporter. Nature 496:533-536. doi: 10.1038/nature12042.
41. Perez-Torras S, Vidal-Pla A, Cano-Soldado P, Huber-Ruano I, Mazo A, Pastor-Anglada M. 2013. Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner. Cell Death & Disease 4:e648. doi: 10.1038/cddis.2013.173.
42. Quintiliani M, Persoons L, Solaroli N, Karlsson A, Andrei G, Snoeck R, Balzarini J, Mcguigan C. 2011. Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. Bioorganic & Medicinal Chemistry 19:4338-4345. doi: 10.1016/j.bmc.2011.05.037.
43. Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. 2010. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leukemia Research 34:454-457. doi: 10.1016/j.leukres.2009.07.002.
44. Rau M, Stickel F, Russmann S, Manser CN, Becker PP, Weisskopf M, Schmitt J, Dill MT, Dufour JF, Moradpour D, Semela D, Mullhaupt B, Geier A & Swiss Hepatitis, CCSG. 2013. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. Journal of Hepatology 58:669-675. doi: 10.1016/j.jhep.2012.11.027.
45. Reyes N, Ginter C, Boudker O. 2009. Transport mechanism of a bacterial homologue of glutamate transporters. Nature 462:880-885. doi: 10.1038/nature08616.
46. Ringer AL, Sinnokrot MO, Lively RP, Sherrill CD. 2006. The effect of multiple substituents on sandwich and T-shaped pi-pi interactions. Chemistry: A European Journal 12:3821-3828. doi: 10.1002/chem.200501316.
47. Rose JB, Coe IR. 2008. Physiology of nucleoside transporters: back to the future. Physiology 23:41-48. doi: 10.1152/physiol.00036.2007.
48. Schlessinger A, Yee SW, Sali A, Giacomini KM. 2013. SLC classification: an update. Clinical Pharmacology and Therapeutics 94:19-23. doi: 10.1038/clpt.2013.73.
49. Singh SK, Yamashita A, Gouaux E. 2007. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448:952-956. doi: 10.1038/nature06038.
50. Slugoski MD, Smith KM, Ng AM, Yao SY, Karpinski E, Cass CE, Baldwin SA, Young JD. 2009. Conserved glutamate residues Glu-343 and Glu-519 provide mechanistic insights into cation/nucleoside cotransport by human concentrative nucleoside transporter hCNT3. The Journal of Biological Chemistry 284:17266-17280. doi: 10.1074/jbc.M109.009613.
51. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. 2004. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clinical Cancer Research 10:6956-6961. doi: 10.1158/1078-0432.CCR-04-0224.
52. Suzuki NN, Koizumi K, Fukushima M, Matsuda A, Inagaki F. 2004. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure 12:751-764. doi: 10.1016/j.str.2004.02.038.
53. Wang H, Goehring A, Wang KH, Penmatsa A, Ressler R, Gouaux E. 2013. Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature 503:141-145. doi: 10.1038/nature12648.
54. Wang ZX. 1995. An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule. FEBS Letters 360:111-114. doi: 10.1016/0014-5793(95)00062-E.
55. Waters ML. 2002. Aromatic interactions in model systems. Current Opinion in Chemical Biology 6:736-741. doi: 10.1016/S1367-5931(02)00359-9.
56. Yao SY, Ng AM, Slugoski MD, Smith KM, Mulinta R, Karpinski E, Cass CE, Baldwin SA, Young JD. 2007. Conserved glutamate residues are critically involved in Na+/nucleoside cotransport by human concentrative nucleoside transporter 1 (hCNT1). The Journal of Biological Chemistry 282:30607-30617. doi: 10.1074/jbc.M703285200.
57. Zhang J, Smith KM, Tackaberry T, Visser F, Robins MJ, Nielsen LP, Nowak I, Karpinski E, Baldwin SA, Young JD, Cass CE. 2005. Uridine binding and transportability determinants of human concentrative nucleoside transporters. Molecular Pharmacology 68:830-839.
58. Zhang J, Sun X, Smith KM, Visser F, Carpenter P, Barron G, Peng Y, Robins MJ, Baldwin SA, Young JD, Cass CE. 2006. Studies of nucleoside transporters using novel autofluorescent nucleoside probes. Biochemistry 45:1087-1098. doi: 10.1021/bi0520535.
59. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, Cass CE. 2003. Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Molecular Pharmacology 64:1512-1520. doi: 10.1124/mol.64.6.1512.
60. Zhou X, Levin EJ, Pan Y, Mccoy JG, Sharma R, Kloss B, Bruni R, Quick M, Zhou M. 2014. Structural basis of the alternating-access mechanism in a bile acid transporter. Nature 505:569-573. doi: 10.1038/nature12811.